Biohaven's Obesity Drug Seeks to Build Muscle, Challenge GLP-1s

NEW HAVEN, Conn. – March 19, 2026 – As the global market for weight-loss drugs continues its explosive growth, Biohaven Ltd. is advancing a novel candidate that aims to redefine what successful treatment looks like. The company announced today it has completed enrollment for a pivotal Phase 2 study of taldefgrobep alfa, an investigational therapy designed not just to reduce weight, but to improve body composition by simultaneously decreasing fat and increasing muscle mass.

The move positions taldefgrobep alfa as a potential challenger and a complementary therapy in a field dominated by GLP-1 agonists like Wegovy and Zepbound. While highly effective at shedding pounds, these blockbuster drugs have raised concerns about the significant loss of lean muscle mass that can accompany fat reduction. Biohaven is betting that its approach, focused on "high-quality weight loss," can offer a more holistic and healthier long-term solution for people living with obesity. Topline data from the fully enrolled study are expected in the second half of 2026.

Beyond the Scale: The Quest for Quality Weight Loss

For decades, the primary goal of obesity treatment has been a lower number on the scale. However, a growing consensus among clinicians suggests that the quality of weight lost is as important as the quantity. Losing significant muscle along with fat can negatively impact metabolic rate, physical strength, and overall health, particularly as individuals age.

This is the precise challenge Biohaven aims to address. Taldefgrobep alfa is a myostatin-activin pathway inhibitor (MAPI), a class of drugs that works through a completely different mechanism than current market leaders. It targets and inhibits myostatin and other related proteins that naturally put the brakes on muscle growth and promote fat accumulation. By blocking these signals, taldefgrobep is designed to essentially flip a switch in the body, encouraging the growth of lean muscle while simultaneously reducing adipose tissue.

"We are at a watershed moment in the treatment of obesity, brought on by the introduction of highly effective therapies like the GLP-1 agonists," stated Frank Greenway, M.D., Professor and Chief Medical Officer at Pennington Biomedical Research Center. "To realize optimal long-term health outcomes, however, we will need to look beyond maximizing weight reduction and remain vigilant around the importance of muscle mass in overall health and wellness. Investigational medications, like taldefgrobep, with the potential to meaningfully reduce body weight and adipose tissue, while increasing muscle mass can be an important addition to the anti-obesity armamentarium."

A Promising Pivot Backed by Data

Taldefgrobep alfa is not a new molecule, but its application in obesity represents a strategic pivot based on compelling data from previous trials for other conditions. The drug was previously studied for neuromuscular disorders, including a Phase 3 trial in patients with Spinal Muscular Atrophy (SMA). While that study did not meet its primary endpoint related to motor function, a closer look at the secondary outcomes revealed a powerful and consistent effect on body composition.

In the SMA trial, participants treated with taldefgrobep achieved a statistically significant reduction in total body fat accumulation of 9.7% compared to placebo. At the same time, they saw a 2.1% increase in muscle mass and a 1.2% benefit in bone mineral density. These results were consistent across various patient subgroups, providing a strong scientific rationale to redeploy the drug for obesity.

Earlier Phase 1 studies in healthy adults further bolstered this case, showing that just 29 days of dosing led to significant reductions in total body fat of over 6% with a commensurate increase in lean muscle mass of up to 4%. Critically, the drug has demonstrated a favorable safety profile across more than 700 trial participants. Rates of muscle and gastrointestinal side effects—which have complicated the development of other MAPI drugs—have been comparable to placebo, making it a potentially well-suited candidate for chronic weight management.

Navigating a Crowded and Competitive Market

Biohaven enters the obesity arena at a time of unprecedented competition and market value, with analysts projecting the sector could exceed $100 billion by the end of the decade. The company is not positioning taldefgrobep to simply replace GLP-1s, but to offer a differentiated alternative or a powerful combination partner.

"We are excited to evaluate taldefgrobep, as both a once-weekly and once-monthly dosing regimen, in an obese patient population," said Peter Ackerman, M.D., Senior Vice President of Clinical Development at Biohaven. "We believe taldefgrobep could represent an important new agent, as monotherapy and in combination with the current standard of care, that can help optimize high-quality weight loss in people living with obesity."

Preclinical studies in obese mouse models support this dual strategy. When used alone, taldefgrobep generated significant reductions in fat and body weight while increasing lean mass. When combined with a GLP-1 agonist, the benefits were additive, suggesting a future where patients might take both types of drugs to achieve maximum fat loss while preserving or even building muscle. This could be a game-changer for ensuring better long-term metabolic health and physical function.

The newly enrolled Phase 2 proof-of-concept study will be the first major test of this hypothesis in a dedicated obesity population. The randomized, double-blind, placebo-controlled trial involves approximately 150 adults across 20 U.S. sites. Participants will use a self-administered autoinjector for either once-weekly or once-monthly doses over a 24-week period. The study’s primary goal is to measure the change in total body weight, but the secondary measures—assessing changes in total body fat and total lean mass—will be where the drug’s true potential for differentiation is revealed. As the world awaits the results in 2026, Biohaven's bold strategy could pave the way for a new, more sophisticated era in the fight against obesity.